166964-20-1

Basic information

• Product Name: 5-(4-Methoxyphenyl)-2-thiophenesulfonyl chloride
• Synonyms: 5-(4-Methoxyphenyl)-2-thiophenesulfonyl chloride
• CAS NO: 166964-20-1
• Molecular Weight: 288.776
• Mol File: 166964-20-1.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 5-(4-Methoxyphenyl)-2-thiophenesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-Methoxyphenyl)-2-thiophenesulfonyl chloride(166964-20-1)
• EPA Substance Registry System: 5-(4-Methoxyphenyl)-2-thiophenesulfonyl chloride(166964-20-1)

Safety Data

• Hazardous Substances Data: 166964-20-1(Hazardous Substances Data)

Upstream product

• 780018-27-1 C₁₁H₁₀O₄S₂ 
• 10026-13-8 phosphorus pentachloride 
• 166964-19-8 N-[5-(4-methoxyphenyl)thiophene-2-sulfonyl]pyrrole 
• 42545-43-7 2-(4-methoxyphenyl)thiophene 

Downstream Products

• 458558-84-4 C₂₃H₃₀N₂O₇S₂ 

Relevant articles and documents

Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13

The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would therefore be a novel disease modifying therapy for the treatment of arthritis. Our efforts have resulted in the discovery of a series of carboxylic acid inhibitors of MMP-13 that do not significantly inhibit the related MMP-1 (collagenase-1) or tumor necrosis factor-α (TNF-α) converting enzyme (TACE). It has previously been suggested (but not proven) that inhibition of the latter two enzymes could lead to side effects. A promising carboxylic acid lead 9 was identified and a convergent synthesis developed. This paper describes the optimization of 9 and the identification of a compound 24f for further development. Compound 24f is a subnanomolar inhibitor of MMP-13 (IC50 value 0.5 nM and Ki of 0.19 nM) having no activity against MMP-1 or TACE (IC50 of >10000 nM). Furthermore, in a rat model of MMP-13-induced cartilage degradation, 24f significantly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition, p 0.05) and at 10 mg/kg (40% inhibition, p 0.05).

Certain azacycloalkyl substituted acetic acid derivatives

Compounds of the formula (I) wherein R represents OH or NHOH; R1 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic ac

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.